Plasma Cell Neoplasms (PDF)

Name: Plasma Cell Neoplasms
Brand: Springer-Verlag GmbH
SKU: 69964849
Price: 74.89 EUR
Availability: OnlineOnly

A Morphologic, Cytogenetic and Immunophenotypic Approach (Sprache: Englisch)

Schreiben Sie einen Kommentar zu "Plasma Cell Neoplasms".

Merken

Mehr zum Inhalt Autorenporträt Video

eBook (pdf) 74.89 €

Buch (Gebunden) 106.99 €

sofort als Download lieferbar

Bestellnummer: 69964849

Printausgabe 106.99 €

eBook (pdf) -30% 74.89 €

Download bestellen

Verschenken

37 DeutschlandCard Punkte sammeln

Lastschrift, Kreditkarte, Paypal, Rechnung
Kostenloser tolino webreader

Produktdetails

Produktbeschreibung
Autorenporträt
eBook Hilfe
Biblio. Angaben / Produktdetails

Produktinformationen zu „Plasma Cell Neoplasms (PDF)“

This volume provides a comprehensive, state-of-the art review on the field of diagnostic hematopathology as it is applied to patients with plasma cell neoplasms. The book places particular emphasis on immunophenotypic data - immunohistochemistry and flow cytometry - as well as cytogenetics, and discusses how these ancillary data can predict prognosis and chemotherapeutic response. It also provides a concise yet comprehensive summary of the current status of the field that will help guide patient management and stimulate investigative efforts.

Written by experts in their fields, Plasma Cell Neoplasms serves as a very useful resource for physicians and researchers interested in plasma cell myeloma diagnosis, therapy, and research.

Autoren-Porträt

Dr. Linden is an Assistant Professor in the Division of Hematopathology within the Department of Laboratory Medicine and Pathology. In addition, he is the Assistant Director of the Special Hematology Laboratory. As a graduate student, Dr. Linden's thesis work helped develop a new mouse model of multiple myeloma. Dr. Linden completed residency and fellowship training in Hematopathology at the University of Washington. He now attends on the University of Minnesota Medical Center's Hematopathology and Flow Cytometry services. Dr. Linden continues to have a strong interest in plasma cell and other hematopoietic neoplasms and enjoys research that applies his clinical skills to improving clinical laboratory diagnoses and predicting clinical outcomes. More specifically, he is investigating optimum diagnostic methods for monitoring residual disease in myeloma patients and developing diagnostic tests to predict chemotherapeutic sensitivity of the neoplastic plasma cells. In addition, he greatly values resident/fellow education and mentorship.